OXB honoured at 2025 CDMO Leadership Awards Europe

Summary by AI BETAClose X

Oxford Biomedica PLC (OXB) announced it has been recognized as a Champion in the 'Cell & Gene Therapy' category at the 2025 CDMO Leadership Awards Europe. This Champion title was awarded to the highest-scoring CDMO, based on feedback from biopharmaceutical professionals. The recognition highlights OXB's excellence in quality, innovation, and service across its global network, driven by increased demand for its end-to-end CDMO services. OXB has 30 years of experience in viral vectors.

Disclaimer*

UK 100

Latest directors dealings